Corporate Banner
Satellite Banner
Technology
Networks
Scientific Communities
 
Become a Member | Sign in
Home>News>This Article
  News
Return

Adocia Strengthens its Diabetic Foot Ulcer Patent Portfolio

Published: Thursday, January 16, 2014
Last Updated: Thursday, January 16, 2014
Bookmark and Share
The patent on the BioChaperone® polymer used in the PDGF composition recently granted in the United States.

Adocia has announced that it has been granted two patents. The first patent is granted in Japan for the BioChaperone PDGF composition and the second in the United States for the BioChaperone polymer. Both patents will protect Adocia’s findings in the field of chronic wound healing, especially for diabetic foot ulcers.

The BioChaperone PDGF product has been successfully tested in a phase II clinical trial in India for the treatment of diabetic foot ulcers. This product is protected by two families of patents.

The first one covers the complexes between BioChaperone polymers and PDGF; the second covers BioChaperone polymers.

The patent on the complexes was granted in Europe and the United States in 2012 (cf. press release of June 13, 2012). The inclusion of Japan now extends the coverage to 29 countries.

Twenty-three are in Europe and the rest are the United States, Australia, Mexico, Russia and South Africa. This patent provides protection until September 26, 2026.

The BioChaperone polymers, a proprietary technology specifically developed by Adocia, are covered by the second patent. The US Patent and Trademark Office (USPTO) recently granted this patent.

Protection of these BioChaperone polymers is now established in the United States, Australia, China, Russia, France and South Africa. It is valid until September 26, 2027.

“We are very pleased with the positive outcome on two of our strategic patent families, especially because they have been granted by the very demanding national American and Japanese patent offices. Our product for treating diabetic foot ulcer is patent protected until at least 2026,” said Remi Soula, director of business development and intellectual property at Adocia. “The granting of these patents consolidates our strong portfolio of 22 patent families, of which six have been granted US patents.”

“We are actively pursuing the clinical development of the BioChaperone PDGF product for the treatment of diabetic foot ulcer. These patents cover the major markets we are targeting. Moreover, we hope to receive authorization to launch the phase III clinical trial in India very soon,” said Olivier Soula, delegate general director and R&D director.


Further Information

Join For Free

Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 2,900+ scientific posters on ePosters
  • More Than 4,200+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

Adocia Reports Positive Results from Phase IIa Clinical Study of BioChaperone® Lispro
The ultra-fast action of BioChaperone Lispro should make a positive impact on short and long-term glycemic control, improving the medical benefit for patients.
Friday, April 11, 2014
Adocia Confirms Positive Clinical Results for its BioChaperone® Combo
BioChaperone Combo is the first combination based on insulin glargine to show a fast and long action in type I diabetic patients.
Friday, March 21, 2014
Adocia Launches Phase IIa Clinical Trial for its Ultra-fast Acting Formulation of Analog Insulin
The aim is to confirm on type I diabetic patients the positive results obtained during phase I.
Tuesday, January 07, 2014
Adocia Signs an Exclusive License on a Nanotechnology
Preclinical results have already demonstrated its remarkable action on solid tumors.
Monday, December 09, 2013
Adocia Announces Initiation of a Clinical Trial on its Combination of Glargine and Lispro
This phase I/II clinical trial on Type I diabetics seeks to compare the performance of this Combo based on insulin Glargine with HumalogMix®.
Monday, November 18, 2013
Adocia Announces Revenues of EUR 4.7 M for the Third Quarter of 2013
The company maintained available cash at EUR 22.7 M.
Thursday, October 24, 2013
Adocia Reacquires Exclusive Development Rights to Ultra-Fast Acting Insulin Analog
Adocia and Lilly terminate collaboration.
Tuesday, July 30, 2013
Adocia Announces its Phase III Development Program for the Treatment of DFU
This program has been validated by scientific advice from the European Medicines Agency.
Wednesday, March 20, 2013
Adocia Announces a Strengthened Intellectual Property on its Lead Project for its Chronic Wounds Treatment
USPTO and EPO have issued a patent to Adocia covering BioChaperone PDGF formulations for chronic wound treatment.
Thursday, June 14, 2012
Adocia Reports Positive Phase II Clinical Results for the Treatment of Diabetic Foot Ulcer
Adocia’s spray formulation of PDGF-BB, combined with BioChaperone®, has been evaluated versus Regranex®, gel of PDGF-BB.
Tuesday, April 24, 2012
Adocia Reports Positive Phase I Clinical Results on HinsBet®, a Fast-Acting Human Insulin
Study on healthy volunteers of a formulation using Adocia’s BioChaperone® platform showed fast onset of action, excellent local tolerance, absence of pain and low inter-patient variability.
Wednesday, March 16, 2011
Scientific News
Criminal Justice Alcohol Program Linked to Decreased Mortality
Institute has announced that in the criminal justice alcohol program deaths dropped by 4.2 percent over six years.
Charting Kidney Cancer Metabolism
Changes in cell metabolism are increasingly recognized as an important way tumors develop and progress, yet these changes are hard to measure and interpret. A new tool designed by MSK scientists allows users to identify metabolic changes in kidney cancer tumors that may one day be targets for therapy.
Improving Regenerative Medicine
Lab-created stem cells may lack key characteristics, UCLA research finds.
Tick Genome Reveals Secrets of a Successful Bloodsucker
NIH has announced that decipher the genome of the blacklegged tick which could lead to new tick control methods.
"Dark Side" of the Transcriptome
New approach to quantifying gene "read-outs" reveals important variations in protein synthesis and has implications for understanding neurodegenerative diseases.
Individuals' Medical Histories Predicted by their Noncoding Genomes
Researchers have found that analyzing mutations in regions of the genome that control genes can predict medical conditions such as hypertension, narcolepsy and heart problems.
'Molecular Movie' Opens Door to New Cancer Treatments
An international team of scientists led by the University of Liverpool has produced a 'structural movie' revealing the step-by-step creation of an important naturally occurring chemical in the body that plays a role in some cancers.
New Source of Mutations in Cancer
Recently, a new mutation signature found in cancer cells was suspected to have been created by a family of enzymes found in human cells called the APOBEC3 family.
Advancing Synthetic Biology
Living systems rely on a dizzying variety of chemical reactions essential to development and survival. Most of these involve a specialized class of protein molecules — the enzymes.
Madison Researchers Begin Work on Zika Virus
Work will start with basic questions about Zika virus infection.
Scroll Up
Scroll Down
Skyscraper Banner

Skyscraper Banner
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
2,900+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
4,200+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FOR FREE!